ClinicalTrials.gov
ClinicalTrials.gov Menu

Phosphate Microvascular Study

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03594539
Recruitment Status : Not yet recruiting
First Posted : July 20, 2018
Last Update Posted : July 20, 2018
Sponsor:
Collaborator:
San Diego Veterans Healthcare System
Information provided by (Responsible Party):
Veterans Medical Research Foundation

Brief Summary:

Elevated phosphate concentrations in the blood have been associated with multiple negative health outcomes in patients with chronic kidney disease as well as in the general population. These negative outcomes include an increased risk of vascular complications like heart attack and stroke. While complications like heart attack and stroke reflect obstructive disease in large blood vessels, recent evidence suggests that elevated phosphate concentrations may first lead to disease in small blood vessels.

This single site clinical trial will randomize 20 veterans with end stage renal disease on hemodialysis to either a phosphate binder or placebo and evaluated for changes in their microvascular function using laser-Doppler flowmtery and nail-fold capillaroscopy.


Condition or disease Intervention/treatment Phase
End Stage Renal Disease Hyperphosphatemia Other: Withholding standard phosphate binder Not Applicable

Detailed Description:

Project Background: Recent studies have suggested that increased serum phosphate and phosphate intake may acute impair microvascular blood flow. However, this has never been directly tested using imaging techniques that directly measure microvascular flow. The end-stage renal disease population on hemodialysis at the VA San Diego is an ideal population to evaluate this effect.

Project Question: Does reduction of serum phosphate through the use of a phosphate binder (lanthanum carbonate) increase microvascular blood flow in persons with ESRD? Project Methods: The investigators propose a 4 week, randomized, double-blinded, placebo controlled, single-center, crossover trial. Participants will have their microvascular function assessed at the baseline of the study using laser-Doppler flowmetry and nail-fold capillaroscopy. They will then be randomized to either lanthanum carbonate or placebo for 2 weeks. Microvascular measurements will be repeated at the end of the 2 week period. Participants will then cross-over to the other study arm. After 2 weeks in the other study arm, they will have microvascular measurements repeated and the trial will then be complete. The primary outcome of the study will be the % change in skin blood flow after heating from 31 degrees Celsius to 44 degrees Celsius. This will be compared within each individual after they complete each arm of the study. Changes seen on nail-fold capillaroscopy, acceptability, safety, and adherence will be key secondary outcomes.


Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 20 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Intervention Model Description: Participants will be randomized to either lanthanum carbonate or placebo for 2 weeks. They will then be assigned to the other arm of the study. They will be in the alternate arm for 2 weeks and then complete the study,
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Masking Description: The pharmacy dispensing the drug will be responsible for generating placebo and distributing drug. The investigators, care providers and patient will not have access to this data. Study outcomes will be comparing arms but not with knowledge of which arm occurred when.
Primary Purpose: Diagnostic
Official Title: The Effects of Phosphate on Microvascular Function
Estimated Study Start Date : July 18, 2018
Estimated Primary Completion Date : January 1, 2021
Estimated Study Completion Date : July 17, 2021

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Kidney Failure

Arm Intervention/treatment
No Intervention: Standard
Participants will have their hyperphosphatemia managed with lanthanum carbonate 1 g with meals and 500 mg with snacks as per typical care, for 2 weeks.
Placebo Comparator: Intervention
Participants will take a placebo instead of standard care with a phosphate binder, for 2 weeks.
Other: Withholding standard phosphate binder
In this trial, placebo represents the intervention and not the control. Standard therapy for hyperphosphatemia in end-stage renal disease includes treatment with a phosphate binder. In this trial the intervention will be to withhold the phosphate binder and use placebo instead. In this way the effect of a higher serum phosphate can be evaluated.




Primary Outcome Measures :
  1. % Change in flux of blood after skin heating to 44 C as measured using laser-Doppler flowmtery. [ Time Frame: Performed at initial study visit, at the end of the first arm of the study (Day 14) and again at the end of the second arm of the study (Day 28) ]
    Flux of blood through skin will be measured using a Perimed PF5000. This will be performed at baseline in a temperature controlled room. Baseline skin measurements will be made at 31C. Skin will then be heated to 44 C. The percent change will be the outcome. This outcome will be compared within each person at the conclusion of each arm. Measurements will all be made on the Monday or Tuesday, the day of the participant's first dialysis treatment of the week. Measurements will be made prior to dialysis.


Secondary Outcome Measures :
  1. Change in capillary count seen post occlusion from pre occlusion, as determined by nail-fold capillaroscopy. [ Time Frame: Performed at initial study visit, at the end of the first arm of the study (Day 14) and again at the end of the second arm of the study (Day 28) ]
    Participants will undergo nail fold capillaroscopy using a CapiScope (KK Technology, Honiton United Kingdom) at baseline and then at the end of each treatment arm. Using a capillarascope a capillary count will be made. After measurement a BP cuff will be inflated to 200 mm Hg occlude flow to a single digit for 1 minute. 30 sec after release the count will be made again. This change will be compared within individuals between measurements made at the completion of each arm in the study. Measurements will all be made on the Monday or Tuesday, the day of the participant's first dialysis treatment of the week. Measurements will be made prior to dialysis. Values at the end of each treatment arm will be compared.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   21 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Diagnosis of ESRD on hemodialysis (HD) for >90 days.
  • Age >21.
  • Capacity to understand and sign informed consent as assess by principal investigator.
  • On a phosphate binder with stable dose for >2 weeks.
  • Serum phosphate at screening visit of <7.0.

Exclusion Criteria:

  • Pregnancy.
  • Actively breastfeeding.
  • Use of oral contraceptives.
  • Inability to take oral medications.
  • History of medication non-compliance as assessed by the treating physician.
  • Patients currently enrolled in another trial.
  • Planned or expected surgical procedure during study period.
  • Planned or expected hospitalization during study period.
  • Corrected serum calcium greater than 10.2 mg/dl.
  • Serum intact PTH >1000 pg/ml
  • Albumin < 3 g/dl.
  • Allergy or intolerance to lanthanum carbonate.
  • Principal investigator deems patient to be unsuitable.
  • Non-English speaking persons. (Study performed at VA, therefore do not anticipate this represents a significant portion of the population).

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03594539


Contacts
Contact: Charles Ginsberg, MD 8585528585 ext 2243 cginsberg@ucsd.edu
Contact: Joachim Ix, MD 8585528585 ext 7528 joeix@ucsd.edu

Sponsors and Collaborators
Veterans Medical Research Foundation
San Diego Veterans Healthcare System

Publications:
Responsible Party: Veterans Medical Research Foundation
ClinicalTrials.gov Identifier: NCT03594539     History of Changes
Other Study ID Numbers: VAH170095
First Posted: July 20, 2018    Key Record Dates
Last Update Posted: July 20, 2018
Last Verified: July 2018
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description: de-identified data may be shared at end of study
Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Informed Consent Form (ICF)
URL: http://

Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Product Manufactured in and Exported from the U.S.: Yes

Keywords provided by Veterans Medical Research Foundation:
ESRD
Microvascular
Hyperphosphatemia
LDF

Additional relevant MeSH terms:
Kidney Failure, Chronic
Hyperphosphatemia
Renal Insufficiency, Chronic
Renal Insufficiency
Kidney Diseases
Urologic Diseases
Phosphorus Metabolism Disorders
Metabolic Diseases